Osteoclast giant cell tumor of the pancreas is important to recognize, as prognosis is often favorable. Osteoclast giant cell tumor of the pancreas is a morphological variant of pancreatic adenocarcinoma, a diagnosis typically associated with a less than 5% five-year survival rate. Of pancreatic tumors, 95% develop from the exocrine portion of the pancreas, with only 2% of those being benign. Pancreatic adenocarcinoma typically presents late, most commonly as abdominal pain due to local invasion by tumor. Mortality is high, as metastases and lymph node invasion are already present. Conversely, osteoclast giant cell tumors have a predilection for local spreading, are slower to metastasize, and rarely metastasize to lymph nodes, affording a better prognosis. A more favorable prognosis is associated with en bloc resection without evidence of nodal metastasis. If pleomorphic giant cells are mixed with osteoclastic cells, the clinical course is more variable with a tendency toward extreme aggressiveness. Most patients have a survival of less than 1 year with a median survival of 11 months, though a range of 4 months to 10 years exists. Our patient had tumor-negative margins and lymph nodes at the time of resection with no evidence of metastatic disease. She did not undergo any postoperative chemotherapy or radiation therapy. She is currently disease-free with no evidence of recurrence at 3 years from surgery. In patients able to undergo a successful curative resection (only 20% of patients), median survival time ranges from 12 to 19 months, and the 5-year survival rate is 15% to 20%. The best predictors of long-term survival after surgery are a tumor diameter smaller than 3 cm, no nodal involvement, negative resection margins, and diploid tumor DNA content.